Offers an overview of adenosine antagonists and Parkinson's disease. Delineates a novel mechanism and concept of adenosine receptor antagonists, explaining groundbreaking research in biochemistry, molecular biology, medicinal chemistry, electrophysiology, pharmacology, and neurochemistry. Discusses the development of a novel non-dopaminomimetic agent for Parkinson's disease, presents a new mechanism of action of adenosine receptor antagonists in motor function, and proposes a hypothesis of adenosine receptor function in the striatum. Kase is involved in pharmaceutical research and development at a Japanese company; Richardson teaches pharmacology at the University of Cambridge; Jenner is affiliated with the Neurodegenerative Diseases Research Center at King's College London. Annotation c. Book News, Inc., Portland, OR (booknews.com)
This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.
Key Features
* Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
* Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
* Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
Proposes a hypothesis of adenosine A2A receptor function in the striatum
* Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.
Key Features
* Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
* Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
* Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
Proposes a hypothesis of adenosine A2A receptor function in the striatum
* Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
Papildus informācija
Key Features * Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease * Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease * Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function Proposes a hypothesis of adenosine A2A receptor function in the striatum * Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
H. Kase, Introductory Remarks: Adenosine A2A Receptor Antagonists: A
Novel Approach to the Treatment of Parkinson's Disease.
S.J. Augood, P.C. Emsom, and D.G. Standaert, Localisation of Adenosine
Receptors in Brain and Periphery.
J. Shimada and F. Suzuki, Medicinal Chemistry of Adenosine Receptors in Brain
and Periphery.
A. Karasawa, Overview of the Physiology and Pharmacology of Adenosine in the
Peripheral System.
H. Nonaka and M. Ichimura, Biochemical Characterizatoin of Adenosine Agonists
and Antagonists.
A. Mori and T. Shindou, Physiology of Adenosine Receptors in the Striatum:
Regulation of Striatal Projection Neurons.
P. Richardson and M. Kurokawa, The Regulation of Neurotransmitter Release in
Basal Ganglia by Adenosine Receptor Agonists and Antagonists in Vitro and in
Vivo.
A. Dixon and P. Richardson, Control of Gene Expression in the Basal Ganglia
Induced by Adenosine Receptors.
S. Aoyama, J.-H. Baik, H. Kase, and E. Borrelli, Knockout Mice in the Study
of Dopaminergic Diseases.
S. Shiozaki, S. Ichikawa, J. Nakamura, and Y. Kuwana, Effects of Adenosine
Receptors Experimental Models of Cognition and Motor Behaviour.
T. Kanda and P. Jenner, Actions of Adenosine Antagonists in a Primate Model
of Parkinson's Disease.
A. Tahar, R. Grondin, L. Gregoire, A. Mori, H. Kase, and P.J. Bedard,
Selective Adenosine A2A Receptor Antagonism as an Alternative Therapy for
Parkinson's Disease: A Study in Nonhuman Primates.
M. Nomoto, Neurobiology of Adenosine Receptors: Adenosine and its Metabolites
in Movement Disorders.
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinsons disease. He has spent the major part of his career at Kings College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of Kings College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinsons disease patient-carer groups across the UK.
